Mood and Anxiety Disorders Clinical Trials
The mission of the Mood and Anxiety Disorders Program is to discover innovative, new therapies for patients suffering from treatment-resistant mood and anxiety disorders in order to improve the quality of life for these individuals and their families. The program pursues excellence in patient-oriented research, clinical care, education and community outreach, with a spirit of beneficence, humility and integrity.
Individuals who have not responded favorably to a variety of therapies for Major Depressive Disorder are considered to have treatment-resistant depression and are of particular interest to our program.
If you are depressed, have bipolar disorder or generalized anxiety disorder and feel that your current medication is not working well enough, or you meet the requirements below, then you may be eligible to participate in one of our research studies.
Links to our program’s current clinical trials are below. Patients who participate in research may be reimbursed for travel and parking expenses.
- Mechanisms, Prediction and Treatment of Short-Term Risk for Suicidal Behavior, Version 2 (H-38275)
- Glutamate Receptor and Kynurenine Pathway Functioning in the Pathobiology of Gulf War Illness (H-40948)
- Electrophysiological Biomarkers of Kynurenine Pathway Modulator AV-101 in Healthy Volunteers: Treating Suicidal Veterans (H-41830)
- NMDA Receptor Modulation for Hyperarousal in PTSD (H-36371)
- Ketamine for Treatment Resistant Late-Life Depression (H-36574)
- Treatment Resistant Depression: Augmentation Versus Switch (H-40432)
- Treatment Resistant Depression: ECT Versus Ketamine (H-40701)
- Developing Neuronal KCNQ Channel Modulators for Mood Disorders (H-40062)
Who Is Eligible for Our Studies?
Patients who meet the following requirements may be eligible to participate in our programs associated clinical studies.
- Men and women diagnosed with Major Depressive Disorder (MDD), Generalized Anxiety Disorder, Bipolar Disorder, or Post-Traumatic Stress Disorder (PTSD)
- Patients between the ages of 18 and 80
- Patients not currently abusing street drugs or alcohol
- Patients not diagnosed with unstable medical or neurological illnesses
- Patients willing to obtain copies of medical records from previous psychiatrist(s)
If you think you qualify for one of our studies, please contact us using one of the following options:
Where Is Our Research Conducted?
Our clinical research is conveniently located at various Baylor affiliate sites throughout Harris County while the majority of our research is conducted at:
Jamail Specialty Care Center
1977 Butler Blvd.
Houston, TX 77030
Map to Jamail
Michael E. DeBakey VA Medical Center
2002 Holcombe Blvd.
Houston, TX 77030
Map to MEDVAMC
Ben Taub Hospital
1502 Taub Loop, 2nd Floor
Houston, TX 77030
Map to Ben Taub
Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 1;74(4):399-405.
Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, Robinson Beale R. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. Neuropsychopharmacology. 2017 May;42(6):1179-81.
Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar;42(4):844-53.
Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar;76(3):247-52.